DE69634472D1 - Adrenal-Cortikosteroide enthaltende therapeutische Zusammensetzung zur äusserlichen Anwendung für Dermatitis-Behandlung - Google Patents

Adrenal-Cortikosteroide enthaltende therapeutische Zusammensetzung zur äusserlichen Anwendung für Dermatitis-Behandlung

Info

Publication number
DE69634472D1
DE69634472D1 DE69634472T DE69634472T DE69634472D1 DE 69634472 D1 DE69634472 D1 DE 69634472D1 DE 69634472 T DE69634472 T DE 69634472T DE 69634472 T DE69634472 T DE 69634472T DE 69634472 D1 DE69634472 D1 DE 69634472D1
Authority
DE
Germany
Prior art keywords
dermatitis
therapeutic composition
clathrate
aqueous solution
external use
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69634472T
Other languages
English (en)
Other versions
DE69634472T2 (de
Inventor
Hajime Yamada
Akira Yamada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CAC Corp
Original Assignee
CAC Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CAC Corp filed Critical CAC Corp
Publication of DE69634472D1 publication Critical patent/DE69634472D1/de
Application granted granted Critical
Publication of DE69634472T2 publication Critical patent/DE69634472T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
DE69634472T 1995-12-11 1996-04-10 Adrenal-Cortikosteroide enthaltende therapeutische Zusammensetzung zur äusserlichen Anwendung für Dermatitis-Behandlung Expired - Lifetime DE69634472T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP34600695 1995-12-11
JP7346006A JP2920611B2 (ja) 1995-12-11 1995-12-11 皮膚炎の治療外用剤

Publications (2)

Publication Number Publication Date
DE69634472D1 true DE69634472D1 (de) 2005-04-21
DE69634472T2 DE69634472T2 (de) 2006-02-16

Family

ID=18380498

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69634472T Expired - Lifetime DE69634472T2 (de) 1995-12-11 1996-04-10 Adrenal-Cortikosteroide enthaltende therapeutische Zusammensetzung zur äusserlichen Anwendung für Dermatitis-Behandlung

Country Status (14)

Country Link
US (1) US5885978A (de)
EP (1) EP0780129B1 (de)
JP (1) JP2920611B2 (de)
KR (1) KR0181763B1 (de)
CN (1) CN1153571C (de)
AT (1) ATE290883T1 (de)
AU (1) AU705996B2 (de)
CA (1) CA2173403C (de)
DE (1) DE69634472T2 (de)
DK (1) DK0780129T3 (de)
ES (1) ES2240987T3 (de)
HK (1) HK1004979A1 (de)
SG (1) SG48460A1 (de)
TW (1) TW431889B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9826656D0 (en) 1998-12-03 1999-01-27 Novartis Ag Organic compounds
IT1319665B1 (it) * 2000-11-17 2003-10-23 Pharma Biotech Ltd Addotti di corticosteroidi con polimeri polisaccaridici naturali.
EP1216712A1 (de) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Einschlusskomplexe von Drospirenone und Cyclodextrinen
EP1216713A1 (de) * 2000-12-20 2002-06-26 Schering Aktiengesellschaft Zusammensetzungen von Estrogen-Zyklodextrin Komplexe
ATE446096T1 (de) 2002-06-03 2009-11-15 Cac Corp Topische präparate zur behandlung von dermatitis
FR2842106B1 (fr) * 2002-07-11 2006-07-14 Centre Nat Rech Scient Dispersions aqueuses de particules nanometriques ou micrometriques pour l'encapsulation de composes chimiques
KR100564153B1 (ko) * 2002-11-28 2006-03-27 주식회사 에이치 엔 비티 아토피성 피부염을 개선시키는 조성물
US8128954B2 (en) 2004-06-07 2012-03-06 California Institute Of Technology Biodegradable drug-polymer delivery system
JP2008501772A (ja) * 2004-06-11 2008-01-24 シンジェンタ リミテッド 炎症性皮膚状態を寛解するための方法
JP5456802B2 (ja) * 2012-01-23 2014-04-02 株式会社Ｃａｃ 細胞遊走促進剤及び創傷治療用の経皮吸収剤
JP6313118B2 (ja) * 2014-05-16 2018-04-18 株式会社Cac ＩｇＥ抑制剤

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5231019B2 (de) * 1973-10-16 1977-08-12
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
JPS61246130A (ja) * 1985-04-24 1986-11-01 Japan Fine Chem Kk 水性皮膚及び毛髪化粧料
US4877774A (en) * 1987-09-09 1989-10-31 The United States Of America As Represented By The Department Of Health And Human Services Administration of steroid hormones
DE68901043D1 (de) * 1988-01-14 1992-04-30 Akzo Nv Waessriges pharmazeutisches praeparat.
US5019562A (en) * 1988-01-19 1991-05-28 The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation Growth inhibiting agent and the use thereof
JPH0795311B2 (ja) * 1988-06-30 1995-10-11 日本電気株式会社 二重化処理装置
US5229370A (en) * 1988-08-15 1993-07-20 Ammeraal Robert N Water soluble branched beta cyclodextrin steroid complex
JP2681527B2 (ja) * 1990-02-15 1997-11-26 ジャパンファインケミカル株式会社 細胞活性促進外用剤
GB9012663D0 (en) * 1990-06-07 1990-08-01 Erba Carlo Spa Galenic formulations containing cyclodextrins
JP2578048B2 (ja) * 1992-05-22 1997-02-05 株式会社 シーエーシー 循環瀘過装置
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
JP3535883B2 (ja) * 1993-06-25 2004-06-07 井関農機株式会社 作業機連結装置
JPH0756417A (ja) * 1993-08-09 1995-03-03 Ricoh Co Ltd 回転型現像装置
JP2772619B2 (ja) * 1994-06-28 1998-07-02 株式会社シーエーシー 多糖類水溶液用循環風呂

Also Published As

Publication number Publication date
AU5056096A (en) 1997-06-19
ATE290883T1 (de) 2005-04-15
SG48460A1 (en) 1998-04-17
CA2173403A1 (en) 1997-06-12
CN1153571C (zh) 2004-06-16
EP0780129A3 (de) 2000-07-19
JPH09157171A (ja) 1997-06-17
ES2240987T3 (es) 2005-10-16
KR970032871A (ko) 1997-07-22
US5885978A (en) 1999-03-23
JP2920611B2 (ja) 1999-07-19
CA2173403C (en) 2000-05-16
DK0780129T3 (da) 2005-06-20
TW431889B (en) 2001-05-01
AU705996B2 (en) 1999-06-03
KR0181763B1 (ko) 1999-05-01
HK1004979A1 (en) 1998-12-18
CN1151866A (zh) 1997-06-18
EP0780129A2 (de) 1997-06-25
DE69634472T2 (de) 2006-02-16
EP0780129B1 (de) 2005-03-16

Similar Documents

Publication Publication Date Title
DE69634472D1 (de) Adrenal-Cortikosteroide enthaltende therapeutische Zusammensetzung zur äusserlichen Anwendung für Dermatitis-Behandlung
FI961098A0 (fi) Menetelmä progestogeniä ja estrogeniä sisältävän korvikkeen valmistamiseksi
DK0595796T3 (da) Fremgangsmåde til behandling af androgen-relaterede sygdomme
DE69133214D1 (de) Medikamente zur topischen anwendung von sexualhormonen zur behandlung des trockenen auges, und verfahren zu ihrer herstellung und anwendung
PT740650E (pt) Co-farmacos como um metodo de administracao controlada de farmacos
ATE179715T1 (de) Verfarhren zur herstellung von 3-alpha-hydroxy, 3-beta-substituierten pregnan-derivaten
DE69320646D1 (de) Verfahren zur behandlung von krebs durch kombinationstherapie mit 2'-halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff
BR0110487A (pt) Composição farmacêutica e método de tratamento de doenças de disfunção cognitiva em um mamìfero
DE69637730D1 (de) Verfahren zur in vito vorbehandlung von myoblasten vor deren transplantation
ATA29495A (de) Zusammensetzung und verfahren zur prävention und behandlung von entzündungen mit immunglobulin a
KR960701648A (ko) Pdgf와 비타민 d를 함유하는 조골세포 성장 자극 조성물(oesteoblast growth stimulating compostion containing pdgf and vitamind)
ID28160A (id) Sistem pengobatan untuk pemberian fenilasetilglutamina, fenilasetilisoglutamina dan/atau fenilasetat.
ES2017808A6 (es) Un metodo para prepara una composicion para inhibir el crecimiento indeseado o patologico de celulas o tejidos.
DE59600683D1 (de) Verwendung von Trospiumchlorid zur Herstellung eines Arzneimittels zur Behandlung von Blasenkrankheiten
ATE230609T1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
DE69417397T2 (de) Lösung, die igf-1 enthält
KR940021064A (ko) 프레그네인 유도체의 사용 방법
DE60026883D1 (de) Methoden und zusammensetzungen zur behandlung von schmerzen
NO982935L (no) Hyaluronsyre reseptor bindemiddel og anvendelse derav
BR9709989A (pt) Processos para tratamento de uma doenca de planta, para preparacão de uma substância ou composicão para tratamento de doenca de planta e para fertilizacão de uma planta, para fertilizacao de uma planta, substâncias ou composicões para tratamento de uma doenca de planta e para fertilizacão de uma planta, e, uso das mesmas.
MX9207493A (es) Composicion farmaceutica que contiene compuestos de trioxolano y diperoxido.
DE69228869D1 (de) Stabilisierte antikörperfragmente
ATE209495T1 (de) Antiatherosclerotische mittel
ATE291431T1 (de) Verwendung von dextrinsulfat zur behandlung von sehr vasculären tumoren
ATE318612T1 (de) Methoden und zusammensetzungen zur behandlung der hyperlipidämie

Legal Events

Date Code Title Description
8364 No opposition during term of opposition